MedTrace Logo

A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies

NCT05862259 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-07-14

No results posted yet for this study

Summary

In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy

Conditions

  • Malignant Tumor
  • Immunotherapy
  • Artificial Intelligence

Sponsors & Collaborators

  • Xinqiao Hospital of Chongqing

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2025-08-10
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05862259 on ClinicalTrials.gov